Company Description
iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers worldwide.
The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them.
Its marketplace offers human biospecimens, including Biofluids, such as whole blood, plasma, serum, urine, saliva, sputum, nasopharyngeal material, and cerebral spinal fluid; Solid tissue comprising fresh, fixed, and cryopreserved tissue, as well as formalin-fixed paraffin embedded blocks, slides, and curls; and Hematopoietic stem and immune cells, including bone marrow, cord blood, whole blood, or sub-components of these tissues, such as peripheral blood mononuclear cells and other isolated cell types.
The company serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions.
iSpecimen Inc. was incorporated in 2009 and is headquartered in Woburn, Massachusetts.
| Country | United States |
| Founded | 2009 |
| IPO Date | Jun 17, 2021 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 24 |
| CEO | Katharyn Field |
Contact Details
Address: 8 Cabot Road Woburn, Massachusetts 02420 United States | |
| Phone | 781 301 6700 |
| Website | ispecimen.com |
Stock Details
| Ticker Symbol | ISPC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 0001558569 |
| CUSIP Number | 45032V108 |
| ISIN Number | US45032V2079 |
| Employer ID | 27-0480143 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Katharyn Field | Chief Executive Officer, President, Secretary and Treasurer |
| Yuying Liang | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 1, 2025 | 8-K | Current Report |
| Nov 21, 2025 | 8-K | Current Report |
| Nov 21, 2025 | DEF 14A | Other definitive proxy statements |
| Nov 17, 2025 | 10-Q | Quarterly Report |
| Nov 14, 2025 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Nov 10, 2025 | PRER14A | Filing |
| Nov 7, 2025 | 8-K | Current Report |
| Nov 3, 2025 | PRE 14A | Other preliminary proxy statements |
| Nov 3, 2025 | 8-K | Current Report |
| Oct 23, 2025 | S-3 | Registration statement under Securities Act of 1933 |